{"id":9213,"date":"2025-09-08T22:55:47","date_gmt":"2025-09-08T20:55:47","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/"},"modified":"2025-09-08T22:55:48","modified_gmt":"2025-09-08T20:55:48","slug":"la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/","title":{"rendered":"La FDA \u00e9tend l&rsquo;utilisation de vonvendi pour la maladie de von Willebrand"},"content":{"rendered":"<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2025\/fda-expands-use-of-von.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/2025\/fda-expands-use-of-von.jpg\" data-sub-html=\"\">\n<figure class=\"article-img\">\n<\/figure><\/div>\n<\/div>\n<p>La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 une utilisation \u00e9largie de vonvendi (facteur Von Willebrand (recombinant)) pour une utilisation prophylactique de routine chez les adultes atteints de tous les types de troubles du sang Von Willebrand (VWD), ainsi que pour le traitement \u00e0 la demande des \u00e9pisodes de saignement et de l&rsquo;utilisation p\u00e9riop\u00e9ratoire chez les enfants avec VWD.<\/p>\n<p>Cette approbation a \u00e9t\u00e9 achev\u00e9e en cours d&rsquo;examen prioritaire avec la d\u00e9signation de m\u00e9dicaments orphelins. Vonvendi n&rsquo;a pr\u00e9c\u00e9demment \u00e9t\u00e9 approuv\u00e9 que pour le traitement \u00e0 la demande des \u00e9pisodes de saignement et l&rsquo;utilisation p\u00e9riop\u00e9ratoire chez les adultes et une utilisation pr\u00e9ventive uniquement chez les adultes avec le type de VWD le plus grave, de type 3. Maintenant, Vonvendi est le produit facteur Von Willebrand non d\u00e9riv\u00e9 de Von Willebrand approuv\u00e9 pour les \u00c9tats-Unis.<\/p>\n<p>De multiples \u00e9tudes cliniques ont montr\u00e9 l&rsquo;efficacit\u00e9 de Vonvendi dans le traitement des \u00e9pisodes de saignement et l&rsquo;utilisation dans la gestion p\u00e9riop\u00e9ratoire chez les patients atteints de VWD de tous \u00e2ges. Il a \u00e9galement montr\u00e9 un succ\u00e8s pour la pr\u00e9vention des \u00e9pisodes de saignement chez les adultes atteints de VWD. Les effets ind\u00e9sirables les plus courants (\u2265 2% des patients dans les essais cliniques) comprenaient des maux de t\u00eate, des vomissements, des naus\u00e9es, des \u00e9tourdissements et des d\u00e9mangeaisons.<\/p>\n<p>\u00ab\u00a0Cette approbation d\u00e9montre la flexibilit\u00e9 de la FDA dans l&rsquo;\u00e9valuation des applications de la th\u00e9rapeutique pour traiter les maladies rares\u00a0\u00bb, a d\u00e9clar\u00e9 Vinay Prasad, MD, directeur du Centre FDA Center for Biologics Evaluation and Research, dans un communiqu\u00e9. \u00ab\u00a0Lorsque nous voyons le trifecta du m\u00e9canisme d&rsquo;action plausible, de la pharmacologie robuste \/ science biologique et des donn\u00e9es de soutien \u00e0 l&rsquo;\u00e9tude clinique, nous agissons rapidement m\u00eame si ces donn\u00e9es sont d\u00e9riv\u00e9es d&rsquo;une petite \u00e9tude de la taille de l&rsquo;\u00e9chantillon.\u00a0\u00bb<\/p>\n<p>L&rsquo;approbation de Vonvendi a \u00e9t\u00e9 accord\u00e9e \u00e0 Takeda.<\/p>\n<p>                                        <!-- print only --><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 une utilisation \u00e9largie de vonvendi (facteur<\/p>\n","protected":false},"author":1,"featured_media":9214,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[5504,447,478,248,8,6556,6555,6557],"class_list":["post-9213","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-etend","tag-fda","tag-lutilisation","tag-maladie","tag-pour","tag-von","tag-vonvendi","tag-willebrand","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>La FDA \u00e9tend l&#039;utilisation de vonvendi pour la maladie de von Willebrand - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA \u00e9tend l&#039;utilisation de vonvendi pour la maladie de von Willebrand - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 une utilisation \u00e9largie de vonvendi (facteur\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-08T20:55:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-08T20:55:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/09\/1757364947_La-FDA-etend-lutilisation-de-vonvendi-pour-la-maladie-de.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"819\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"La FDA \u00e9tend l&rsquo;utilisation de vonvendi pour la maladie de von Willebrand\",\"datePublished\":\"2025-09-08T20:55:47+00:00\",\"dateModified\":\"2025-09-08T20:55:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/\"},\"wordCount\":344,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/09\/1757364947_La-FDA-etend-lutilisation-de-vonvendi-pour-la-maladie-de.jpg\",\"keywords\":[\"\u00e9tend\",\"FDA\",\"Lutilisation\",\"maladie\",\"pour\",\"von\",\"vonvendi\",\"Willebrand\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/\",\"name\":\"La FDA \u00e9tend l'utilisation de vonvendi pour la maladie de von Willebrand - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/09\/1757364947_La-FDA-etend-lutilisation-de-vonvendi-pour-la-maladie-de.jpg\",\"datePublished\":\"2025-09-08T20:55:47+00:00\",\"dateModified\":\"2025-09-08T20:55:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/09\/1757364947_La-FDA-etend-lutilisation-de-vonvendi-pour-la-maladie-de.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/09\/1757364947_La-FDA-etend-lutilisation-de-vonvendi-pour-la-maladie-de.jpg\",\"width\":1280,\"height\":819,\"caption\":\"La FDA \u00e9tend l'utilisation de vonvendi pour la maladie de von Willebrand\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA \u00e9tend l&rsquo;utilisation de vonvendi pour la maladie de von Willebrand\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA \u00e9tend l'utilisation de vonvendi pour la maladie de von Willebrand - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/","og_locale":"fr_FR","og_type":"article","og_title":"La FDA \u00e9tend l'utilisation de vonvendi pour la maladie de von Willebrand - RVH-Synergie.org","og_description":"La Food and Drug Administration des \u00c9tats-Unis a approuv\u00e9 une utilisation \u00e9largie de vonvendi (facteur","og_url":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/","og_site_name":"RVH-Synergie","article_published_time":"2025-09-08T20:55:47+00:00","article_modified_time":"2025-09-08T20:55:48+00:00","og_image":[{"width":1280,"height":819,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/09\/1757364947_La-FDA-etend-lutilisation-de-vonvendi-pour-la-maladie-de.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"La FDA \u00e9tend l&rsquo;utilisation de vonvendi pour la maladie de von Willebrand","datePublished":"2025-09-08T20:55:47+00:00","dateModified":"2025-09-08T20:55:48+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/"},"wordCount":344,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/09\/1757364947_La-FDA-etend-lutilisation-de-vonvendi-pour-la-maladie-de.jpg","keywords":["\u00e9tend","FDA","Lutilisation","maladie","pour","von","vonvendi","Willebrand"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/","url":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/","name":"La FDA \u00e9tend l'utilisation de vonvendi pour la maladie de von Willebrand - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/09\/1757364947_La-FDA-etend-lutilisation-de-vonvendi-pour-la-maladie-de.jpg","datePublished":"2025-09-08T20:55:47+00:00","dateModified":"2025-09-08T20:55:48+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/09\/1757364947_La-FDA-etend-lutilisation-de-vonvendi-pour-la-maladie-de.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/09\/1757364947_La-FDA-etend-lutilisation-de-vonvendi-pour-la-maladie-de.jpg","width":1280,"height":819,"caption":"La FDA \u00e9tend l'utilisation de vonvendi pour la maladie de von Willebrand"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/la-fda-etend-lutilisation-de-vonvendi-pour-la-maladie-de-von-willebrand\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"La FDA \u00e9tend l&rsquo;utilisation de vonvendi pour la maladie de von Willebrand"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/9213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=9213"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/9213\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/9214"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=9213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=9213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=9213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}